Overview Brilinta DaYu Study Status: Completed Trial end date: 2015-09-30 Target enrollment: Participant gender: Summary A multicenter, single arm, open label, Phase IV study to evaluate safety and to describe the incidence of major cardiovascular events of ticagrelor in Chinese patients with acute coronary syndrome Phase: Phase 4 Details Lead Sponsor: AstraZenecaTreatments: Ticagrelor